Annals of Neurology · 2006 · 300 citations · 30 references
Life SciencesNeurologyNeuroscienceMotor NeuroscienceNeurodegenerationNeurologic PharmacotherapyAmyotrophic Lateral SclerosisMotor Neuron Disease EvaluationNeurodegenerative Disease PharmacotherapyMaximal Voluntary ContractionMaximum Voluntary Contraction TestingMotor Impairment AssessmentMotor Unit Number EstimationPreclinical Drug TestingProstaglandin InhibitorsReduced Grip Strength
OBJECTIVE: To determine whether chronic treatment with celecoxib, a cyclooxygenase-2 inhibitor that has been shown to be beneficial in preclinical testing, is safe and effective in amyotrophic lateral sclerosis (ALS). METHODS: A double-blind, placebo-controlled, clinical trial was conducted. Three hundred research subjects with ALS were randomized (2:1) to receive celecoxib (800 mg/day) or placebo for 12 months. The primary outcome measure was the rate of change in upper extremity motor function measured by the maximum voluntary isometric contraction strength. Secondary end points included safety, survival, change in cerebrospinal fluid prostaglandin E(2) levels, and changes in the rate of decline of leg and grip strength, vital capacity, ALS Functional Rating Scale-Revised, and motor unit number estimates. RESULTS: Celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, ALS Functional Rating Scale-Revised, or affect survival. Celecoxib was well tolerated and was not associated with an increased frequency of adverse events. Prostaglandin E(2) levels in cerebrospinal fluid were not elevated at baseline and did not decline with treatment. INTERPRETATION: At the dosage studied, celecoxib did not have a beneficial effect on research subjects with ALS, and it was safe. A biological effect of celecoxib was not demonstrated in the cerebrospinal fluid. Further studies of celecoxib at a dosage of 800 mg/day in ALS are not warranted.
30
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Lucette Lacomblez, Gilbert Bensimon, Vincent Meininger et al. · The Lancet · 1996 · 1.3K citations
Prostaglandins stimulate calcium-dependent glutamate release in astrocytes
Paola Bezzi, Giorgio Carmignoto, Lucia Pasti et al. · Nature · 1998 · 1.1K citations
Functional Role of Caspase-1 and Caspase-3 in an ALS Transgenic Mouse Model
Mingwei Li, Victor Ona, Christelle Guégan et al. · Science · 2000 · 716 citations